Article detail · 2014
A comparison of the effects of infliximab adalimumab and pentoxifylline on rats with non alcoholic steatohepatitis
Journal
The Turkish Journal of GastroenterologyISSN 1300-4948
The ISSN points to another catalog journal; the name is from the YÖKSİS record.
- Year
- 2014
- Type
- article
Data source split
- YÖKSİS YÖKSİS article record
- YÖKSİS venue The Turkish Journal of Gastroenterology
- Catalog match (ISSN) Turkish Journal of Gastroenterology
- OpenAlex OpenAlex enrichment (abstract, citations, topics)
Abstract
English (OpenAlex)
BACKGROUND/AIMS: Non-alcoholic steatohepatitis (NASH) lacks effective medical treatment. Since tumor necrosis factor alpha (TNF-α) plays an important role in NASH pathogenesis, we aimed to investigate drugs affecting TNF-α as possible treatment options during the development of NASH. MATERIALS AND METHODS: A total of 35 rats were divided into five groups and evaluated over a 6 week period. One group received a normal diet alone or in combination with the administration of infliximab, adalimumab or pentoxifylline. RESULTS: NASH was successfully established in the MCD diet group. Levels of TNF-α were effectively suppressed in the three groups that received anti-TNF agents. No statistically significant differences were observed between the three agents in terms of the histological NASH score. CONCLUSION: Our study showed that the anti-TNF agents infliximab, adalimumab, and pentoxifylline effectively suppress TNF-α. Although these drugs did not prevent the development of NASH, they were able to slightly reverse the NASH histopathology score and positively affect liver function tests.
Topics
- Liver Disease Diagnosis and Treatment
- Liver Diseases and Immunity
- Pancreatitis Pathology and Treatment
Primary topic Liver Disease Diagnosis and Treatment